Dr. Padbury has more than 35 years of scientific expertise and leadership in the pharmaceutical and biotechnology industries. He is currently Senior Vice President of Clinical Pharmacology and Translational Sciences for Pfizer’s Oncology Division, where he leads global strategy and operations across pharmacokinetics, pharmacodynamics, biomarkers, and companion diagnostics. Guy joined Pfizer through its 2023 acquisition of Seagen, where he was SVP of Translational Science. Prior to Seagen, he was Chief Development Officer at Scorpion Therapeutics and held senior executive roles including SVP of Preclinical Development at Merck Research Laboratories. Earlier, he led global functions in pharmacokinetics, bioanalytical sciences, and drug metabolism at both Pfizer (2006–08) and Amgen (2008–15). His career also spans influential scientific and managerial positions at Dow Chemical, Upjohn, Pharmacia & Upjohn, Pharmacia, and a previous tenure at Pfizer. Across his career, Guy has contributed to more than 50 successful global drug registrations—from small molecules to biotherapeutics—impacting most major therapeutic areas worldwide. In addition to his corporate leadership, Guy is deeply engaged in advancing science and innovation through board and advisory roles. He currently serves on the Board of Advisors for the University of Illinois, Illinois Ventures, LLC, and the Advisory Board for Illini Angels. He has also served on the NIH General Medical Sciences Advisory Council, the University of Washington School of Pharmacy Corporate Advisory Board, and the Board of Trustees for the Franklin Institute. Guy holds a PhD and MS in Biochemistry from the University of Illinois and a BS in Chemistry from Butler University.